V 181
Alternative Names: Dengue Tetravalent Vaccine; V-181Latest Information Update: 13 Jun 2025
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer Butantan Institute; Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
- Class Attenuated vaccines; Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Dengue
Most Recent Events
- 11 Jun 2025 Phase-III clinical trials in Dengue (In children, In adolescents, Prevention) in Singapore (SC) (NCT07013487)
- 12 Dec 2024 Butantan Institute in collaboration with Merck Sharp & Dohme completes a phase II trial in Dengue (Prevention, In adults) in Brazil (SC) (NCT05710224)
- 15 Feb 2023 Butantan Institute in collaboration with Merck Sharp & Dohme initiates a phase II trial in Dengue (Prevention, In adults) in Brazil (SC) (NCT05710224)